OLIN Corp 8-K

What Happened
Olin Corporation and Huntsman Corporation signed an Agreement and Plan of Merger on June 15, 2026 to combine in an all‑stock “merger of equals.” Under the deal, each outstanding share of Huntsman common stock will convert into 0.5476 shares of Olin common stock (the Exchange Ratio). The combined company will be named OlinHuntsman Corporation and headquartered in The Woodlands, Texas, with Kenneth Lane as CEO and Peter Huntsman as non‑executive chair.

Key Details

• Merger Agreement signed June 15, 2026; Olin and Huntsman boards unanimously approved the transaction.
• Exchange Ratio: 0.5476 Olin shares per Huntsman share; no fractional shares—cash paid in lieu for fractions.
• Governance and leadership: 10‑member combined board (4 directors from Olin, 4 from Huntsman, plus Kenneth Lane and Peter Huntsman). Phil Lister named CFO; Todd Slater named Chief Integration Officer.
• Shareholder approvals required: Huntsman stockholder vote and either (a) >2/3 of Olin shares for a direct merger or (b) a majority vote for the Olin share issuance option under NYSE rules leading to subsidiary‑merger route.
• Regulatory and filing conditions: Hart‑Scott‑Rodino and other antitrust clearances, effectiveness of an S‑4 registration statement and NYSE listing approval for the merger consideration.
• Break fees and termination: $121,000,000 termination fee in certain circumstances; reimbursement of up to $30,000,000 for documented out‑of‑pocket expenses if approvals fail but fee not payable.
• Voting and Support Agreement: Peter Huntsman and affiliates agreed to vote their Huntsman shares in favor of the merger and against competing proposals.

Why It Matters
This is a major strategic combination in the chemicals sector that will be executed as an all‑stock merger, changing ownership stakes rather than using cash. The exchange ratio, board composition and named executives give a clear view of post‑deal control and leadership. Key next steps for investors are shareholder votes, regulatory approvals, and the filing/effectiveness of the S‑4 and joint proxy — any delays or failed approvals could prevent the deal or trigger termination provisions. Retail investors should review the forthcoming S‑4 and joint proxy/prospectus for details on timing, dilution, governance and how their holdings would be affected.